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A B S T R A C T
Purpose: Perampanel is approved for adjunctive treatment of focal seizures, with or without secondarily
generalised seizures, and for primary generalised tonic-clonic seizures in people with epilepsy aged
12 years. Perampanel was recently approved for monotherapy use for partial seizures in the United
States. This study provides insight into the feasibility of perampanel monotherapy in real-world settings.
Methods: This retrospective, non-interventional, multicentre study (NCT02736162) was conducted
between January 2013 and March 2016 in specialist epilepsy centres in Europe and Russia. Eligible
individuals had a diagnosis of epilepsy and received perampanel primary or secondary monotherapy as
routine clinical care. The primary endpoint was proportion of individuals remaining on perampanel
monotherapy, after conversion from perampanel adjunctive treatment, at 3, 6, 12, 18 and 24 months
(retention rate).
Results: Sixty individuals were in the safety set (female, 63%; white, 97%; aged 18 to <65 years, 73%). Most
(85%) received secondary monotherapy with perampanel. At study cut-off, 68% of individuals were
continuing on perampanel monotherapy (secondary monotherapy: 55%). The median duration of
retention was not calculable due to the high number of individuals ongoing on monotherapy. Twelve
individuals had treatment-emergent adverse events that started during perampanel monotherapy, the
most frequent was dizziness (5%). One serious treatment-emergent adverse event was reported
(pneumonia during adjunctive perampanel treatment).
Conclusions: In this small retrospective study of individuals who received perampanel monotherapy, the
majority maintained monotherapy. Perampanel monotherapy may be an achievable option in some
people with epilepsy.
© 2017 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Perampanel, a selective, non-competitive antagonist of the
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor, is approved for adjunctive treatment of focal seizures
with or without secondarily generalised seizures and for primary
generalised tonic-clonic seizures in people with epilepsy aged
12 years [1,2]. Perampanel was recently approved for
monotherapy use for focal seizures in the United States. Approval
of perampanel as an adjunctive treatment was based on Phase III
clinical trial data in adjunctive settings [3–6] and reﬂects the usualAssociation. This is an open access article under the CC BY-NC-ND license (http://
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AEDs as adjunctive treatments is, however, unique among central
nervous system drugs and can restrict on-label use to polytherapy
settings, which has been associated with increased toxicity,
non-compliance and cost [7,8]. Due to these restrictions and
ethical concerns around the use of placebo-controlled trials for
AED monotherapy [7,9], open-label trials and speciﬁc epilepsy
syndrome indications have been recommended to support
monotherapy use [7].
Perampanel monotherapy has shown anti-seizure effects in
several animal models of epilepsy and status epilepticus [10,11]
but there have been no controlled trials of perampanel mono-
therapy in humans. Real-world evidence may be a useful
approach to explore the feasibility of AED monotherapy in the
clinic. We report the results of a retrospective study evaluating
perampanel monotherapy in the routine clinical care of people
with epilepsy.
2. Methods
2.1. Study design and population
This was a retrospective, non-interventional, multicentre study
to investigate the dosage, efﬁcacy and safety of perampanel given
as monotherapy in routine clinical care to individuals with
epilepsy (Eisai Inc. protocol E2007-G000-504; ClinicalTrials.gov
identiﬁer: NCT02736162). Data were collected retrospectively for
individuals with epilepsy who received perampanel as primary or
secondary (conversion) monotherapy between 1 January 2013 and
1 March 2016 at specialist epilepsy centres across Austria,
Denmark, Germany, Russia, Spain and the United Kingdom
(i.e., countries where perampanel was commercially available
and being prescribed). Primary monotherapy was deﬁned as the
administration of perampanel in the absence of any concomitant
AEDs, and secondary (conversion) monotherapy was deﬁned as
the conversion of perampanel from adjunctive therapy to
monotherapy by withdrawing concomitant AEDs. Those deﬁned
as being on primary monotherapy may have previously taken other
AEDs but would have permanently discontinued these prior to
starting perampanel monotherapy (e.g. due to being in remission
or subject choice), although this information was not speciﬁcally
captured as part of this study.
Cases were identiﬁed by centres from electronic/paper medical
and pharmacy records of individuals who were attending their
usual epilepsy clinic and were prescribed perampanel as mono-
therapy based on the treating clinician’s recommendation.
Given that this was a non-interventional study, the risk to
participants in the study was limited to the possibility of a breach
in their conﬁdentiality with regard to personal identiﬁers or health
information. Anonymised information was collected from medical
records without any involvement or participation of individuals,
and the sponsor had no access to individual medical records.
Where applicable, Independent Ethics Committee and regulatory
authority review and approval were obtained in accordance with
local legislation.
2.2. Data collection
Each centre was responsible for its own data collection and
reporting; available data were entered by centres into paper case
report forms.
Where available, data on AED history, seizure frequency
and safety were collected. Data for evaluation of seizure outcomes
were obtained from medical records or seizure diaries, where
available; if not available, investigator assessment of the
therapeutic response was used.Written informed consent must have been provided by each
individual, or their legally authorised representative, for the use of
the medical records, as per local requirements.
2.3. Objectives and analyses
All individuals who had received at least 1 dose of perampanel
were included in the safety set and all individuals who had
received perampanel and had seizure frequency data available
(including data at pre-perampanel baseline) were included in the
full analysis set.
The primary objective of the study was to assess the retention
rate of perampanel when given as secondary monotherapy in
routine clinical care. Accordingly, the proportions of individuals
remaining on perampanel monotherapy (retention rates) at 3, 6,12,
18 and 24 months were evaluated as primary endpoints, with an
additional analysis at the study cut-off date of 1 March 2016. The
denominators for these retention rates were the numbers of
individuals who could have been exposed for each period of time.
Retention rates were assessed in the safety set for a population of
individuals who speciﬁcally received secondary monotherapy, and
additional analyses included all individuals receiving primary or
secondary monotherapy.
The following secondary endpoints, relating to changes in
seizure frequency, were assessed in the full analysis set: the
proportion of individuals who were seizure free for at least
3 months while receiving perampanel monotherapy; and changes
in seizure frequency between pre-perampanel baseline (up to
3 months prior to the initiation of perampanel) and (1) the last
3 months of perampanel adjunctive treatment (only determined
for individuals who received secondary monotherapy), (2) the ﬁrst
3 months of perampanel monotherapy and (3) the last 3 months of
perampanel monotherapy before the last follow-up (only deter-
mined for individuals with a minimum of 6 months of follow-up).
Speciﬁcally, changes in seizure frequency were assessed as the
following: median percent change in seizure frequency per
28 days; proportions of individuals with a reduction in seizure
frequency of 50% (50% responder rate); and proportions of
individuals with no change or a worsening of seizure frequency,
based on qualitative clinical impression (i.e., investigator response
of “stable/no change” or “worsened”) or seizure frequency (i.e., no
change or an increase in seizure frequency). Seizure-freedom rates
were also assessed at the same 3 time periods; individuals with a
seizure-free status recorded as unknown were included as not
seizure free.
Maximum and median doses of perampanel during adjunctive
treatment and monotherapy were recorded. Other safety end-
points included treatment-emergent adverse events (TEAEs) and
serious TEAEs, assessed in the safety set from the initiation of
perampanel monotherapy until 30 days after the last dose of
perampanel monotherapy.
Other post hoc analyses explored the impact of prior AED use
(including the use of enzyme-inducing AEDs [EIAEDs]) and
epilepsy history. These analyses are described in more detail in
Supplementary Methods A.1 in Appendix A.
3. Results
3.1. Study population and AED exposure
Data collection was started on 19 April 2016 and the last data
items were collected on 14 July 2016. Of 1225 individuals
prescribed perampanel across the centres, 69 (6%) were prescribed
perampanel as monotherapy. Data were provided for 60 individu-
als (from 19 centres) who were included in the safety set; most had
received perampanel as secondary monotherapy (n = 51; 85%)
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individuals included in the full analysis set (secondary mono-
therapy, n = 37; primary monotherapy, n = 3). Disposition is shown
in Fig. 1.
Demographics and clinical characteristics for the safety set are
shown in Table 1. Most were aged between 18 and <65 years
(44/60; 73%), most had been diagnosed with epilepsy 5 years
previously (41/60; 68%) and most were experiencing focal seizures
according to International League Against Epilepsy classiﬁcation
(48/60; 80%).
Of the 60 individuals in the safety set, 14 (23%) had previously
received 1–2 AEDs, 18 (30%) had previously received 3–5 AEDs and
7 (12%) had previously received 6–10 AEDs, which were stopped
before receiving perampanel; the most frequent were levetirace-
tam (n = 27; 45%), valproic acid (n = 20; 33%) and lamotrigine
(n = 19; 32%). The remaining 21 individuals (35%) had not
previously received any other AEDs that were stopped before
receiving perampanel.
Of the 51 individuals in the safety set who had started
perampanel as an adjunctive treatment (prior to conversion to
secondary monotherapy), 42 (82%) were receiving just 1 other AED
at the ﬁrst dose of perampanel and 9 (18%) were receiving 2
other AEDs (none were receiving 3 other AEDs); the most
frequently co-administered AEDs were levetiracetam (n = 11; 22%),
lacosamide (n = 9; 18%) and valproic acid (n = 9; 18%).
3.2. Retention rates
A Kaplan-Meier analysis of time to discontinuation of
perampanel monotherapy treatment is shown in Fig. 2. Due to
insufﬁcient events, it was not possible to calculate the medianFig. 1. Dispoduration of retention and upper conﬁdence interval (lower
conﬁdence interval: 258.0 days). Retention rates at 3 and 6
months were 95% and 74%, respectively (secondary monotherapy:
96% and 71%, respectively; Supplementary Fig. B.1 in Appendix B).
At the study cut-off date, there were 41 individuals (68%)
continuing on perampanel monotherapy; of these, 33 were
receiving perampanel as secondary monotherapy (see disposition
shown in Fig. 1). Conversely, 19 individuals (32%) had discontinued
from perampanel monotherapy, most commonly due to
inadequate therapeutic effect (n = 11) or adverse events (n = 6).
3.3. Changes in seizure frequency
Of the 40 individuals who had seizure frequency data available
and were thus included in the full analysis set, more than half
(n = 22; 55%) were seizure free for at least 3 months at any time
while receiving perampanel primary or secondary monotherapy.
Median percent reductions in seizure frequency, 50% responder
rates and seizure-freedom rates throughout 3-month periods
during adjunctive therapy and monotherapy are shown in
Supplementary Fig. B.2 in Appendix B. For individuals in the full
analysis set, the median number of seizures per 28 days was 3.0 at
baseline, 1.0 during the last 3 months of perampanel adjunctive
treatment and 0.5 throughout the ﬁrst 3 months of perampanel
monotherapy.
Compared with pre-perampanel baseline, there was no change
or worsening of seizure frequency for 9/37 individuals (24%) during
the last 3 months of perampanel adjunctive treatment and 6/40
individuals (15%) throughout the ﬁrst 3 months of perampanel
monotherapy. All other individuals experienced improvements in
seizure frequency.sition.
Table 1
Demographics and clinical characteristics (safety set).
Safety set
(N = 60)
Female, n (%) 38 (63)
Age, n (%)
<12 years 8 (13)
12 to <18 years 6 (10)
18 to <65 years 44 (73)
65 years 2 (3)
Race, n (%)
White 58 (97)
Unknown 1 (2)
Missing 1 (2)
Country, n (%)
Spain 29 (48)
United Kingdom 15 (25)
Russia 12 (20)
Germany 2 (3)
Austria 1 (2)
Denmark 1 (2)
Age at epilepsy diagnosis, n (%)
<12 years 18 (30)
12–17 years 19 (32)
18–64 years 22 (37)
Unknown 1 (2)
Time since epilepsy diagnosis, n (%)
<1 year 4 (7)
1 to <3 years 8 (13)
3 to <5 years 6 (10)
5 to <10 years 15 (25)
10 to <20 years 15 (25)
20 years 11 (18)
Missing 1 (2)
Seizure type, n (%)
Simple partial without motor signs 13 (22)
Simple partial with motor signs 18 (30)
Complex partial 41 (68)
Partial with secondary generalisation 37 (62)
Generalised tonic-clonic 18 (30)
Myoclonic 5 (8)
Absence 6 (10)
Tonic 6 (10)
Clonic 1 (2)
Atonic 1 (2)
ILAE classiﬁcation, n (%)
Focal seizures 48 (80)
IGE 8 (13)
Unknown 3 (5)
Missing 1 (2)
IGE, idiopathic generalised epilepsy; ILAE, International League Against Epilepsy.
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There were 60 individuals in the safety set. All except 1 of these
individuals received a maximum perampanel dose of between 2
and 12 mg, with the remaining individual receiving a maximum
dose of 24 mg (recorded as 20 mg due to database constraints and
considered as 20 mg for all average dose calculations). The
median (range) maximum perampanel dose was 6.0 mg
(2.0–10.0 mg) during adjunctive treatment and 8.0 mg
(4.0–20.0 mg) during monotherapy (overall median maximum
dose, 8.0 mg). The median (range) last daily dose of perampanel
was 6.0 mg (2.0–10.0 mg) during adjunctive treatment and 6.0 mg
(2.0–20.0 mg) during monotherapy.
Total exposure was 1767.0 subject-weeks on adjunctive
perampanel and 2102.1 subject-weeks on perampanelmonotherapy. At the cut-off date, the median duration of
perampanel adjunctive therapy was 6.4 months (range, 2.0–
29.3 months) and perampanel monotherapy had been maintained
for a median of 6.1 months (range, 0.5–44.1 months).
Fifteen individuals had TEAEs that started during adjunctive
perampanel treatment and 12 had TEAEs that started during
perampanel monotherapy (Table 2). The most frequent TEAE was
dizziness (n = 9; 15%).
There was 1 serious TEAE: an episode of pneumonia, which
required hospitalisation, but was not life-threatening; this event
occurred during adjunctive perampanel treatment and not during
perampanel monotherapy. There were no deaths.
3.5. Post hoc analyses
For 14 individuals who received EIAEDs during adjunctive
treatment, the median maximum dose of perampanel was 5.0 mg
during adjunctive treatment and 7.0 mg during monotherapy
(overall 7.0 mg). The median last daily dose of perampanel was
4.0 mg during adjunctive treatment and 6.0 mg during subsequent
monotherapy. TEAEs were experienced by 4/14 individuals (29%)
during adjunctive treatment and 1/14 individuals (7%) during
monotherapy; the most frequent TEAEs were irritability
(adjunctive treatment, n = 2; monotherapy, n = 1) and somnolence
(adjunctive treatment, n = 2; monotherapy, n = 0).
Of these 14 individuals, 11 were continuing monotherapy at
study cut-off; 3 reverted to adjunctive treatment due to inadequate
therapeutic effect. Retention rates for these individuals were 100%
(13/13 individuals) and 83% (10/12) at 3 and 6 months after the
initiation of monotherapy, respectively. By comparison, retention
rates for individuals who did not receive EIAEDs during adjunctive
treatment were 94% (31/33 individuals) and 64% (14/22) at 3 and
6 months after the initiation of monotherapy, respectively. There
were no clear correlations between retention rates and number of
previous AEDs received and stopped prior to the initiation of
perampanel, time since epilepsy diagnosis or epilepsy syndrome
(Supplementary Table C.1 in Appendix C).
In the full analysis set, responder rates indicated that
monotherapy could confer 50% reductions in seizure frequency,
again with no clear correlation with prior AED use or epilepsy
history (Supplementary Table C.2 in Appendix C).
4. Discussion
Our retrospective study included 60 individuals with epilepsy
who received perampanel monotherapy as part of routine clinical
care. The study population was considered to be representative of a
real-world epilepsy population, with many individuals having a
history of focal seizures, many receiving 1–5 AEDs at baseline and
many having had epilepsy for more than 5 years. Most individuals
who received perampanel monotherapy did so following conver-
sion from polytherapy with adjunctive perampanel and other
AEDs, which is the practical route for people to receive
monotherapy with third-generation AEDs. We assume that the
main reason for conversion to secondary monotherapy was to
reduce side effects in people who experienced increased seizure
control or seizure freedom while taking adjunctive perampanel.
Reasons for initiation of primary monotherapy were most likely to
improve compliance (due to perampanel’s once-daily dosing) or
avoid side effects associated with previous regimen(s). The stated
reasons for conversion in each individual case were, however, not
speciﬁcally captured as part of this study.
Many individuals in this retrospective study would not have
met eligibility criteria for prospective clinical trials [9]. Of note, 35%
of individuals had not previously received any other AEDs that
were stopped before initiation of perampanel, whereas individuals
Fig. 2. Kaplan-Meier plot of retention on monotherapy (safety set).
Table 2
Summary of TEAEs that started during perampanel adjunctive treatment or monotherapy (safety set).
Adjunctive treatment
(n = 51)
Monotherapy
(n = 60)
Any TEAE, n (%)a 15 (29) 12 (20)
Any serious TEAE, n (%) 1 (2) 0 (0)
Any TEAE leading to perampanel dose adjustment, n (%) 7 (14) 10 (17)
Withdrawalb 2 (4) 4 (7)
Dose increase 0 (0) 1 (2)
Dose reduction 6 (12) 7 (12)
Most frequent TEAEs (5% of individuals), n (%)
Dizziness 6 (12) 3 (5)
Irritability 5 (10) 2 (3)
Somnolence 4 (8) 1 (2)
Headache 2 (4) 1 (2)
TEAE, treatment-emergent adverse event.
a Excludes 1 non-serious TEAE of anxiety, since the study period of onset was unknown.
b TEAEs leading to withdrawal included dizziness and irritability (2 individuals each), and asthenia, aggression, anxiety and mania (1 individual each).
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previously failed 2 or more AEDs [3,4,6]. This suggests that many
individuals had epilepsy that was not as refractory as those
included in clinical trials.
Most individuals were able to maintain perampanel mono-
therapy, whether given as a primary or secondary monotherapy.
There was also some indication of efﬁcacy with perampanel
monotherapy, as most experienced some improvement in seizure
control, while a smaller proportion had no change. This is
consistent with other previous studies of conversion to AED
monotherapy, including a study of conversion to lacosamide
monotherapy [12].
The duration of perampanel monotherapy (median, 6.1 months)
was considered sufﬁcient to assess safety outcomes. Overall, it was
generally well tolerated in this small population, with no new or
unexpected TEAEs. The most frequently reported TEAEs of
dizziness, irritability, somnolence and headache were also
consistent with the TEAE proﬁle reported in previous clinical
trials [3–6].
Post hoc analyses did not identify any clear or consistent
correlations between retention rates or responder rates and prior
AED use or epilepsy history. There was some variation in
outcomes but this was considered largely attributable to the
inherent variability when dealing with small population sizes. It
should also be considered that there may have been a selectionbias, since only those individuals who did well on adjunctive
treatment would have been converted to monotherapy. Peram-
panel levels may have increased in those individuals who
underwent withdrawal of EIAEDs, which could have had
implications for efﬁcacy and tolerability (note that treating
physicians did not elect to decrease the dose of perampanel in
most of these cases, and only 1 case was associated with TEAEs
during perampanel monotherapy [irritability leading to dose
reduction; friction burn; fractured toe]).
This study has potential limitations, and the retrospective
design and small population size may be key considerations. The
study did not involve a comparator arm; however, in applying an
observational design, a broad, real-world epilepsy population
could be assessed without the limitations of the strict eligibility
criteria associated with controlled trials. In addition, the early
censoring of a large proportion of study subjects meant that
although people were followed for up to 24 months, there were not
enough subjects at time points beyond 6 months to allow
meaningful analyses to be carried out.
Overall, the study may provide an initial insight into the
feasibility of perampanel monotherapy in a real-world setting. The
results indicate that perampanel monotherapy may be an
achievable option for some people with epilepsy, irrespective of
prior AED use. Such initial evidence is useful in determining
whether larger monotherapy trials are warranted and how these
66 A. Gil-Nagel et al. / Seizure 54 (2018) 61–66should be designed, although it remains the case that prospective
trials are associated with inherent challenges.
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